This protease inhibitor shows two different activities, it inhibits both the capsaicin receptor TRPV1 and serine proteases. It partially blocks the capsaicin- and acid-induced response of TRPV1, a receptor of the pain pathway (PubMed:20208578, PubMed:24351908). It also weakly inhibits trypsin and chymotrypsin activity (Ki=0.5 uM and Ki=7 uM, respectively) (PubMed:20208578). In addition, it may also alter tachykinin levels by suppressing endogenous proteases (PubMed:22982418). In vivo, it shows antinociceptive and analgesic activities (PubMed:24351908). It significantly prolongs paw withdrawal latency and blocks heat-induced and chemical-induced acute pain (PubMed:20208578). In addition, it also shows anti-inflammatory and analgesic effects in models of osteoarthritis and rheumatoid arthritis (PubMed:33477357). In vivo, unlike other TRPV1 antagonists whose activity is associated with hyperthermia, this protein has the remarkable feature of dropping core body temperature (PubMed:24351908). Intravenous dose (up to 1mg/kg) has no toxic effect and generates no behavioral disorders in mice. Belongs to the venom Kunitz-type family. Sea anemone type 2 potassium channel toxin subfamily.